Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study

被引:5
|
作者
Ding, Jianghua [1 ]
Leng, Zhaohui [1 ]
Gu, Hong [2 ]
Jing, Xiang [3 ]
Song, Yun [1 ]
机构
[1] Jiujiang Univ, Dept Hematol & Oncol, Affiliated Hosp, Jiujiang, Jiangxi, Peoples R China
[2] Ruichang People Hosp, Dept Hematol & Oncol, Ruichang, Jiangxi, Peoples R China
[3] Lushan People Hosp, Dept Hematol & Oncol, Lushan, Jiangxi, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
etoposide; platinum (EP); anlotinib; transformation; small-cell lung cancer (SCLC); lung adenocarcinoma (LUAD); epidermal growth factor receptor (EGFR); TYROSINE KINASE INHIBITORS; 1ST-LINE TREATMENT; DOUBLE-BLIND; CHEMOTHERAPY; MULTICENTER; PLACEBO; THERAPY;
D O I
10.3389/fonc.2023.1153131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe histological conversion of lung adenocarcinoma (LUAD) into small-cell lung cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment for SCLC patients. The efficacy of etoposide/platinum (EP) as the main treatment is very limited for patients with transformed SCLC. However, little is known about EP plus anlotinib for transformed SCLC. The present study retrospectively explored the clinical response to EP combined with anlotinib in patients with transformed SCLC from LUAD after EGFR-TKI failure. MethodsA total of 10 patients who underwent SCLC transformation from EGFR-TKI-resistant LUAD were retrospectively reviewed from September 1, 2019, to December 31, 2022, in three regional hospitals. All of the patients were treated with the combination regimen of EP and anlotinib for four to six cycles, followed by anlotinib maintenance therapy. The clinical efficacy indices including objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival (mOS), and toxicities were evaluated. ResultsThe median time from EGFR-TKI treatment to SCLC conversion was 20.1 & PLUSMN; 2.76 months (17-24 months). Genetic examination after transformation showed that 90% of the patients retained their original EGFR gene mutations. Additional driver genes were found, including BRAF mutation (10%), PIK3CA mutation (20%), RB1 loss (50%), and TP53 mutation (60%). The ORR and DCR were 80% and 100%, respectively. The mPFS was 9.0 months (95% CI, 7.9-10.1 months), and the mOS was 14.0 months (95% CI, 12.0-15.9 months). Less than 10% of grade 3 toxicities were observed, and no grade 4 toxicity and death events were reported. ConclusionThe EP plus anlotinib regimen appears to be a promising and safe strategy in transformed SCLC patients after EGFR-TKI resistance, which warrants further investigation.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
    Xia Wang
    Zhimin Zeng
    Jing Cai
    Peng Xu
    Pingan Liang
    Yuxi Luo
    Anwen Liu
    BMC Cancer, 21
  • [2] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [3] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [4] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [5] Molecular mechanism of transformation from adenocarcinoma to small-cell lung cancer after EGFR-TKI
    Han, J.
    Zhang, Q.
    Wang, B.
    Zhou, Q.
    Zhang, Z.
    Chuai, S.
    Yang, J-J.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI
    Han, Jiefei
    Zhang, Qiuyi
    Wang, Binchao
    Zhou, Qing
    Yan, Lixu
    Zhang, Zhou
    Chen, Huajun
    Su, Jian
    Xie, Zhi
    Niu, Feiyu
    Wu, Yi Long
    Chuai, Shannon
    Yang, Jinji
    Dong, Zhong-Yi
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1263 - S1264
  • [7] Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance A case report
    Jiang, Yiqian
    Shou, Leyi
    Guo, Qingmin
    Bao, Yanhong
    Xu, Xiaoping
    An, Suhong
    Lu, Jianfeng
    MEDICINE, 2021, 100 (32) : E26911
  • [8] EGFR-Mutant Adenocarcinoma Transform into Small-Cell Lung Cancer: Real or Not
    Zhang, Y.
    Li, R.
    Jiang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1019 - S1020
  • [9] Association between EGFR-TKI Resistance and Efficacy of Radiotherapy for Brain Metastases from EGFR-mutant Lung Adenocarcinoma
    Hirata, Hidenari
    Nakamura, Katsumasa
    Kunitake, Naonobu
    Shioyama, Yoshiyuki
    Sasaki, Tomonari
    Ohga, Saiji
    Nonoshita, Takeshi
    Yoshitake, Tadamasa
    Asai, Kaori
    Inoue, Kouji
    Nagashima, Akira
    Ono, Minoru
    Honda, Hiroshi
    ANTICANCER RESEARCH, 2013, 33 (04) : 1649 - 1655
  • [10] Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study
    Wang, Xia
    Zeng, Zhimin
    Cai, Jing
    Xu, Peng
    Liang, Pingan
    Luo, Yuxi
    Liu, Anwen
    BMC CANCER, 2021, 21 (01)